ClinicalTrials.gg
RecruitingNCT05850923Updated Jul 6, 2023

The Efficacy of Speech Competition Training on Auditory Hallucination in Schizophrenia

An interventional study of speech competition training and the soothing music in Auditory Hallucination, sponsored by Jing SHI. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-07-06.

Sponsored by Jing SHI · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Nov 2022, registered Apr 2023).
  • Started Nov 2022; still recruiting 3 years 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

One hundred schizophrenia patients with auditory hallucinations will be recruited and randomized into group A and group B. Participants of group A will firstly receive a speech competition training for 2 weeks, and those in group B will firstly receive music intervention as placebo treatment. Specifically, speech competition training include voice competition training twice a day in adjunction with drug treatment, and the patients will be required to perform voice-related tasks according to the instruction. The reaction time, accuracy rate and the number of auditory hallucinations during the task will be recorded. On the other hand, the placebo treatment includes soothing music twice a day for a fixed period of time while patients receiving drug treatment. After 2 weeks, the interventions for group A and group B will be switch.

Clinical symptoms will be evaluated using the auditory hallucinations rating scale, positive and negative syndrome scale, belief about voices questionnaire-revised at baseline, 2-week follow up and 4-week follow up. All the data will be analyzed with the Statistical Product and Service Solutions(SPSS) software.

02

Conditions studied

  • Auditory Hallucination

Keywords

  • Schizophrenia
  • Intervention
03

In context

Hallucinations

136 studies on the registry are indexed under Hallucinations; 35 are open to participants now.

This study's planned enrollment of 100 is above the median of 48 across 118 interventional studies indexed under Hallucinations.

Browse Hallucinations studies →

Lead sponsor

This is the only study on the registry with Jing SHI as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fulfilling the diagnostic criteria for schizophrenia as in the International Classification of Diseases (ICD) - 10;
  • Aged 18-55 years old;
  • Education level over 6 years;
  • The score of P3 item in PANSS ≥ 3 points;
  • Taking antipsychotics at a therapeutic dose for at least 1 month, and the symptoms of auditory hallucinations have not been significantly improved, and the score of Auditory Hallucinations Rating Scale (AHRS) is still greater than 18 points;
  • Capable of understanding and singing a written form, and be able to cooperate in completing intervention training and assessments.

Exclusion criteria

Exclusion Criteria:

  • Diagnosing other Axis I mental disorders;
  • A history of severe neurological disease, brain trauma, major physical disease or history of drug dependence;
  • Auditory hallucinations caused by organic brain diseases;
  • Patients who cannot cooperate with the completion of training;
  • Patients with serious suicidal or self injurious behavior;
  • Pregnant and lactating women;
  • History of alcohol abuse;
  • Intellectual impairment (IQ\<70);
  • Patients with hearing impairment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    a speech competition experimental group

    The speech competition training was arranged twice a day, each lasting 15 minutes. The training included word search in sequence, word search out of order and word sorting. Patients need to follow the instructions in time for training. The reaction time, accuracy rate and the number of auditory hallucinations during the task were recorded.

    Other: speech competition training

  • Active comparator
    Control group

    The patient will listen to the soothing music twice a day, each lasting 15 minutes.

    Other: the soothing music

Interventions

  • Otherspeech competition training

    Speech competition training include voice competition training twice a day in adjunction with drug treatment, and the patients will be required to perform voice-related tasks according to the instruction.

  • Otherthe soothing music

    the soothing music

06

What researchers measure

Primary outcomes

  1. Auditory Hallucinations Rating Scale (AHRS)

    The Hoffman Hallucination Rating Scale (AHRS) is a clinical tool used to assess the severity of auditory hallucinations in patients. In current study, the scale is used to evaluate the severity of auditory hallucinations in patients with schizophrenia, mainly from seven aspects: frequency, authenticity, loudness, number of sounds, duration, attention significance, and pain level.

    Time frame: Change of AHRS score from baseline at 2 weeks and 4 weeks respectively

  2. Belief About Voices Questionnaire-Revised (BAVQ-R)

    This scale is a self-assessment scale developed by Chadwick et al., used to measure the beliefs, emotions, and behaviors of patients with auditory hallucinations, with a total of 35 items. Straus et al. reconducted factor analysis on its basis and extracted four factors, namely victim belief (authority belief+malicious belief), goodwill belief, participation in auditory hallucinations, and resistance to auditory hallucinations. The scale items are scored using the Likert 4-level scoring method, with a score of 0-3 and independent scores for each dimension.

    Time frame: Change of BAVQ-R score from baseline at 2 weeks and 4 weeks respectively

Secondary outcomes

  1. Negative and Negative Syndrome Scale (PANSS)

    The Negative and Positive Symptoms Scale is a widely used scale for assessing patients' clinical symptoms. The PANSS scale has a total of 30 items, including three subscales of positive symptoms, negative symptoms and general psychopathological symptoms. Each item is scored 1-7 in increasing order of severity. The sum of the items contained in the factor is the factor score, and the scores of all items are added to obtain the total score.

    Time frame: Change of PANSS score from baseline at 2 weeks and 4 weeks respectively

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Jun 2024, 19 months after the start.

Of 53 non-industry interventional studies with no phase under Hallucinations, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 56. This study's planned 19 months is below that.

Counting every sponsor, half of 53 studies reached it within 37 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2023
First posted
May 9, 2023
StartActual
Nov 15, 2022
Primary completionEst.
Jun 30, 2024
CompletionEst.
Jun 30, 2024
Last update
Jul 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05850923
Lead sponsor
Jing SHI
Responsible party
Jing SHI (Nurse practitioner, Shanghai Mental Health Center) — Sponsor-investigator
First posted
May 9, 2023
Start date
Nov 15, 2022
Primary completion
Jun 30, 2024 (estimated)
Completion
Jun 30, 2024 (estimated)
Last update
Jul 6, 2023

Study contacts

Jing Shi, Bachelor
Contact
1156769381@qq.com
86-13774390145
Qian Guo, M.D.
Contact
guoqian1205@vip.163.com
86-13761005210
Qian Guo, M.D.
principal investigator · Shanghai Mental Health Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion